Availability Archives - Page 8 of 9

Home
/
Projects
/

Availability

Availability refers to sufficient, sustainable and timely supply of new TB vaccines for adults and adolescents. This includes having demand assessed for different population groups, defining policy and evidence needs, and having procurement plans in plans. This follows from the WHO global framework for country introduction of new adolescent and adult TB vaccines (https://www.who.int/publications/m/item/who-global-framework-to-prepare-for-country-introduction-of-new-tb-vaccines-for-adults-and-adolescents)

The impact of alternative delivery strategies for novel tuberculosis vaccines in low-income and middle-income countries: a modelling study

2023

Hypothetical vaccines

We estimated the impact of novel tuberculosis vaccines in low-income and middle-income countries (LMICs) in several delivery scenarios.

The cost and cost-effectiveness of novel tuberculosis vaccines in low- and middle-income countries: A modeling study

2023

Hypothetical vaccines

We assessed future costs, cost-savings, and cost-effectiveness of introducing novel TB vaccines in low- and middle-income countries (LMICs) for a range of product characteristics and delivery strategies.

The potential impact of novel tuberculosis vaccines on health equity and financial protection in low-income and middle-income countries

2023

Hypothetical vaccines

We assessed the potential financial risk protection from introducing novel TB vaccines, and how health and economic benefits would be distributed across income quintiles.

Acceptability and effect on public and cost-effectiveness impact

2023

BCG revaccination, M72/AS01e

Understanding the acceptability of new TB vaccines, and their impact on health, cost-effectiveness, and budget, by socio-economic and risk group, in likely early adopter and other archetype countries.

Systematic review of mathematical models exploring the epidemiological impact of future TB vaccines

2016

Hypothetical vaccines

The aim was to provide a summary of the modeling methodology used, the characteristics of future TB vaccines explored using modeling, and the comparative epidemiological impact of such novel vaccine profiles.

Modelling the health and economic impacts of M72/AS01E vaccination and BCG-revaccination: estimates for South Africa

2023

BCG revaccination, M72/AS01e

we used a mathematical model to estimate the health impact and cost-effectiveness of M72/AS01E and BCG-revaccination in South Africa under a range of vaccine characteristics and delivery assumptions

New tuberculosis vaccines: advances in clinical development and modelling

2020

Hypothetical vaccines

We summarize the mathematical modelling literature used to inform vaccine development, focusing on models that address the epidemiologic impact of new TB vaccines. Finally,we describe the future for TB vaccines in the effort towards TB elimination

Mapping the existing body of knowledge on new and repurposed TB vaccine implementation: A scoping review

2024

BCG revaccination, Hypothetical vaccines, M72/AS01e

By synthesizing the existing body of knowledge, this review offers comprehensive insights into the current state of research on implementation of these TB adults and adolescent vaccines. Offering insights into key dimensions: (1) epidemiological impact, (2) costing, cost-effectiveness, and/or economic impact, (3) acceptability, and the (4) feasibility of implementation; this includes implementation strategies of target populations, and health system capabilities.

An investment case for new tuberculosis vaccines

2022

Hypothetical vaccines

This document summarizes the results of the WHO-commissioned full value proposition for new TB vaccines. It is for use by national and global decision-makers involved in vaccine development and implementation.

TPTVaxx

2024

Vaccines will be introduced in contexts where TPT already exists. Exploration of possible study designs, expected effectiveness, feasibility of integrated approaches is key.